Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

NCT06295549 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped Achieve the proof of concept.

Conditions

Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL: LUCAR-G39P cells product

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Collaborators

[object Object]